Rates today
  • Prime rate 6.75% flat
  • Fed funds 3.63% flat
  • SOFR 3.64% up0.07
  • Treasury 1Y 4.14% up0.11
  • Treasury 10Y 4.65% up0.05
Updated: EST

This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis.

Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.